Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction, announced the completion of dosing in its randomized, double-blind placebo-controlled Phase 2 clinical trial evaluating ANEB-001 as a potential treatment for ACI in healthy subjects challenged with oral THC.

“Completing the dosing in this Phase 2 trial represents an important milestone for the company. Preliminary data showed that a single 10 mg dose of ANEB-001 reduced key symptoms of ACI induced with 30 mg of THC,” said Simon Allen, CEO of Anebulo.

ANEB-001 Clinical Trial: Conducted in the Netherlands by the Centre for Human Drug Research, parts A and B of the Phase 2 study enrolled 134 healthy adults.

"Part B of the Phase 2 trial was an adaptive design that included six cohorts of up to 15 healthy subjects to examine different doses of …

Full story available on